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Abstract. Background/Aim: During screening for compounds which selectively 
suppress growth of human colorectal cancer (CRC) spheroids with mutant (mt) KRAS, 
the uridine analogue, 5-bromouridine (BrUrd) was identified and its derivatives 
explored. Materials and Methods: DNA incorporation in two-dimensional (2D) and 
three-dimensional floating (3DF) cultures was examined with the uridine analogue, 5-
ethynyl-2’-deoxyuridine (EdU). The area of HKe3 CRC spheroids expressing wild type 
(wt) KRAS (HKe3-wtKRAS) and mtKRAS (HKe3-mtKRAS) were measured in 3DF 
culture with 11 BrUrd derivatives. Results: EdU was strongly incorporated into newly 
synthesized DNA from HKe3-mtKRAS cells compared to HKe3-wtKRAS in 2D and 
3DF culture. 3-deaza-cytarabine, which has properties of BrUrd and Cytidine, was the 
most effective inhibitor of HKe3-mtKRAS spheroids with the least toxicity to HKe3-
wtKRAS. Growth suppression of 3-deaza-cytarabine was stronger than cytarabine in 
2D culture, and toxicity was lower than gemcitabine in long-term 3DF culture. 
Conclusion: 3-deaza-cytarabine exhibits properties useful for the treatment of CRC 
patients with mtKRAS.   
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Anticancer nucleosides include several analogues which fall into the categories of 
physiological pyrimidine and purine nucleosides. Pyrimidine analogues are further 
categorised into cytidine and uridine (or thymidine) analogues (1). Several pyrimidine 
analogues were synthesized and evaluated (2), and the first of these analogues to be 
approved by the US Food and Drug Administration (FDA) was the cytidine analogue, 
cytosine β-D-arabinofuranoside hydrochloride (cytarabine), which was approved in 
1969 for the treatment of acute leukemia (3). In 1996, the FDA approved another 
cytidine analogue called 2',2'-difluorodeoxycytidine (gemcitabine) (4). Gemcitabine 
has more favourable pharmacokinetic properties including greater solubility and lower 
toxicity to normal cells than cytarabine both in vitro and in vivo and has been used for 
the treatment of patients with solid tumours, including pancreatic cancers, lung 
cancers and colorectal cancers (CRCs) (5, 6). In these tumours a critically involved 
signalling pathway associated with oncogenic mutations in the Kirsten rat sarcoma 
viral oncogene homologue (KRAS) gene was identified (7). Furthermore, clinical 
studies have shown that patients with mutated (mt) KRAS show a worse response to 
gemcitabine-based therapy than those with wild-type (wt) KRAS (8). However, drugs 
selectively targeting oncogenic KRAS have not yet been clinically developed (9). 
Recently, we established a three-dimensional floating (3DF) culture system to 
preliminary screen chemical libraries which inhibit mtKRAS-mediated signaling (10). 
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As a result, we identified an? uridine analogue, 5-bromouridine (BrUrd), as a novel 
molecule that may be able to selectively target HKe3-mtKRAS spheroids and may 
exhibit low level toxicity to wtKRAS spheroids.  
In order to determine the effects of 11 BrUrd derivatives in CRC with mtKRAS 
in vitro, 3DF culture was performed using the HKe3 cells overexpressing wtKRAS 
(HKe3-wtKRAS) and mtKRAS (HKe3-mtKRAS) (10). Our results suggest that 3-
deaza-cytrabine may be an effective treatment for human colorectal cancer. 
 
Materials and Methods 
 
Reagents. BrUrd derivatives were kindly provided by RIKEN Natural Products 
Depository (NPDepo, Saitama, Japan). Chemical distances were determined by the 
Jaccard similarity index (11). Cytosine β-D-arabinofuranoside 
hydrochloride:cytarabine and gemcitabine hydrochloride were purchased from Sigma-
Aldrich (St.Louis, MO, USA). 
 
EdU incorporation assay. 4 × 104 HKe3-wtKRAS cells and 1 × 104 HKe3-mtKRAS cells, 
which were established in an earlier study (10), were seeded in LabTek 8-chamber 
slides (Nunc, Rochester, NY) for 2D culture or in a 96-well plate with an ultra-low 
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attachment surface and a round bottom (Corning Inc., Corning, NY, USA) for 3DF 
culture at 37ºC for three days. Cells were treated with EdU for an additional 16 h. EdU 
was visualized using the Click-iT™ Plus EdU Imaging Kits Alexa (Life Technologies 
Corporation, Carlsbad, CA, USA) using the manufacturer’s protocol. 
 
Two-dimensional (2D) Cell culture. HKe3-wtKRAS and HKe3-mtKRAS cells were 
cultured in Dulbecco's modified Eagle's medium (DMEM)-high glucose (Life 
Technologies Corporation) supplemented with 10% fetal bovine serum, 1% 
penicillin/streptomycin/Glutamine (Life Technologies Corporation), 600 μg/ml G418 
(Wako, Osaka, Japan), and 2 μg/ml puromycin (Wako) as previously described (10, 
12-19). 
 
3D floating cell culture. HKe3-wtKRAS and HKe3-mtKRAS cells were seeded in 96-
well plates with ultra-low attachment surfaces and round bottoms (Corning Inc.). Cells 
were cultured for 7 days in a CO2 incubator as previously described (10). 
Photomicrographs of cells were taken and analysed using an IN Cell Analyzer 1000 
(GE Healthcare, Little Chalfont, UK) and IN Cell Developer Toolbox (GE Healthcare). 
The relative growth rate was calculated from a comparison of the area of control 
spheroids at day three. 
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Cell growth assay in 2D culture. 4 × 104 HKe3-wtKRAS cells and 1 × 104 HKe3-
mtKRAS cells, which were established as previously described (10), were seeded in 
96-well microplates (Corning) at 37ºC for six days, and the absorbance of formazan 
solutions was measured using a 3-(4,5-dimethlthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay-based Cell Counting Kit-8 (Dojindo, Kumamoto, Japan) 
according to the supplier’s instructions. The relative growth rate was calculated from 
a comparison of the absorbance obtained from cells treated with dimethyl sulfoxide 
(DMSO) alone as a vehicle control. 
 
Statistical analyses. All experiments were performed in triplicate. Data are presented 
as means ± standard deviations. Statistical analyses were performed using unpaired 
two-tailed Student’s t-test in Microsoft Excel. p-Values of less than 0.05 were 
considered statistically significant.  
 
Results 
EdU incorporation in HKe3-wtKRAS and HKe3-mtKRAS cells grown in 2D and 3DF 
cultures. During the first screening, the uridine analogue, BrUrd, was identified as a 
candidate drug that inhibits the growth of HKe3-mtKRAS spheroids but not HKe3-
wtKRAS spheroids (data not shown). A total of 11 BrUrd derivatives were selected 
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from 4000 RIKEN libraries of natural products using chemical distance (11) (Table I). 
To address the hypothesis that BrUrd derivatives would be more strongly incorporated 
into HKe3-mtKRAS cells to suppress the growth of tumour cells than HKe3-wtKRAS 
cells in 2D and 3DF cultures, EdU was used, another uridine analogue, to visualize 
DNA incorporation. Cells were plated at day 0 and treated with EdU overnight at day 
3. EdU staining was performed at day 4 (Figure 1A). EdU was more strongly 
incorporated into HKe3-mtKRAS cells than HKe3-wtKRAS cells in 2D (Figure 1B) and 
3DF (Figure 1C) cultures under the same experimental conditions, suggesting BrUrd 
derivatives, including uridine analogues may be selectively incorporated into tumours 
with mtKRAS and suppress tumour growth.  
 
BrUrd derivatives inhibit the growth of HKe3-mtKRAS spheroids. To examine the 
effects of BrUrd derivatives on cell proliferation, cells were treated with 11 BrUrd 
derivatives or DMSO alone in 3DF culture. To make the volume of HKe3-wtKRAS 
spheroids and HKe3-mtKRAS spheroids at day 3 uniform, 4 × 104 HKe3-wtKRAS cells 
and 1 × 104 HKe3-mtKRAS cells were plated and the area of spheroids was measured 
at days 3 and 7 (Figure 2A). We also established the scoring method shown in Table 
II. The area of HKe3-mtKRAS spheroids with 16.6 µM and 50.0 µM of BrUrd at day 7 
were 0.81fold (p=0.049) and 0.76-fold (p=0.0023) compared to control and were 
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respectively smaller in comparison to those of the HKe3-wtKRAS spheroids treated 
with DMSO alone at day 7 (Figure 2B). The area of HKe3-mtKRAS spheroids with 
16.6 µM and 50.0 µM of 3-deaza-cytarabine at day 7 were 0.76-fold (p=0.0038) and 
0.56-fold (p=0.0009) smaller in comparison to that of HKe3-wtKRAS spheroids treated 
with DMSO alone at day 7, respectively (Figure 2B). These results suggest that 3-
deaza-cytarabine suppresses spheroid growth more than BrUrd at the concentration 
of 16.6 µM. To test the late effect of these drugs from day 3 to day 7, the area of HKe3-
wtKRAS and -mtKRAS spheroids with 16.6 µM and 50.0 µM of BrUrd derivatives at 
day 7 were compared to that at day 3 (Figure 2C). The area of HKe3-wtKRAS and 
HKe3-mtKRAS spheroids with DMSO at day 7, were 1.13-fold and 3.45-fold larger 
than the HKe3-wtKRAS spheroids at day 3, respectively (Figure 2B and 2C). Among 
the BrUrd derivatives showing significant (p<0.05) suppression of growth of HKe3-
mtKRAS spheroids compared to those with DMSO control (3.45), the increased ratio 
with 16.6 µM of BrUrd, 5-Bromo-2'-deoxyuridine (BrdU), NPD7328, azidothymidine 
(AZT), 3-deaza cytarabine, 6-azauridine and NPD6666 from day 3 to day 7 was 1.10, 
1.23, 1.89, 1.76, 1.20, 1.59, and 1.31-fold (Figure 2C ), respectively, while the efficacy 
of 50.0 µM was 1.07, 1.27, 1.28, 1.42, 0.98, 1.45 and 1.19-fold greater (Figure 2C). 
These results suggest that BrUrd (1.07) and 3-deaza-cytarabine (0.98) at 50.0 µM 
concentration showed greater efficacy for growth suppression than the other 
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candidates. On the other hand, the increased ratio of HKe3-wtKRAS spheroids with 
16.6 µM and 50.0 µM of BrUrd, 5-Bromo-2'-deoxyuridine (BrdU), NPD7328, 
azidothymidine (AZT), 3-deaza cytarabine, 6-azauridine and NPD6666 from day 3 to 
day 7 was not significantly decreased compared to that with DMSO control. Notably, 
the increased ratio of HKe3-wtKRAS with 50.0 µM of 3-deaza-cytarabine was 1.14-
fold larger than that with DMSO control (Figure 2C), suggestive of a low cytotoxicity of 
3-deaza-cytarabine.  
 
The efficacy of cytidine analogues for HKe3-wtKRAS and HKe3-mtKRAS cells grown 
in 2D culture. Structurally, 3-deaza-cytarabine is similar with both uridine analogues 
and cytidine analogues. To compare the efficacy of 3-deaza-cytarabine with other 
cytidine analogues which are currently being used in clinical settings, including 
cytarabine and gemcitabine (2), the effect of cytarabine, 3-deaza-cytarabine and 
gemcitabine in 2D culture was first examined. Cells were plated at day 0 and treated 
with drugs from day 0 to day 6 (Figure 3A). An increase in the concentration of 
cytarabine from 0.1 to 5.0 µM did not cause any statistically significant differences in 
cell proliferation of HKe3-wtKRAS and -mtKRAS cells in 2D culture (Figure 3B). While 
culturing cells with 3-deaza-cytarabine and gemcitabine show growth suppression of 
both HKe3-wtKRAS and -mtKRAS cells in 2D culture (Figure 3C and 3D). These 
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results suggest that the growth suppression of 3-deaza cytarabine and gemcitabine is 
stronger than that of cytarabine in HKe3-wtKRAS and -mtKRAS cells in 2D culture. 
The 0.1 µM concentration of 3-deaza-cytarabine did not show an effect on cell 
proliferation (Figure 3C), however, the 0.1 µM of gemcitabine significantly decreased 
proliferation of both HKe3-wtKRAS and -mtKRAS cells in 2DC (Figure 3D), suggesting 
that the cytotoxicity of gemcitabine is higher than that of 3-deaza-cytarabine. 
 
The long-term effect of BrdU, 3-deaza-cytarabine, and gemcitabine for HKe3-wtKRAS 
and-mtKRAS spheroids. To determine the cytotoxicity of pyrimidine (uridine and 
cytidine) analogues, including BrdU, 3-deaza-cytarabine and gemcitabine with low 
concentrations of drugs during long term exposure, a long-term 3DF culture was 
performed. Cells were plated at day 0 and treated with drugs in serial dilutions and the 
area of spheroids was measured every three to four days until day 27 (Figure 4A). The 
area of HKe3-wtKRAS spheroids with DMSO alone at day 27 was 2.48-fold larger 
when compared to that at day 3 (Figure 4B). On the other hand, the area of HKe3-
mtKRAS spheroids with DMSO alone at day 27 were 15.75-fold larger when compared 
to that at day 3 (Figure 4B). Treatment of HKe3-mtKRAS spheroids by serially-diluted 
3-deaza-cytarabine showed that the concentration required to achieve a 50% of the 
maximal inhibition in cell proliferation is approximately 0.5 µM (Figure 4B). The area 
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of HKe3-wtKRAS spheroids with BrdU and 3-deaza-cytarabine at day 17 is similar with 
DMSO control (Figure 4C), suggesting that both drugs do not display cytotoxicity to 
cells with wtKRAS. On the other hand, cytotoxicity of gemcitabine was observed in 
both HKe3-wtKRAS and -mtKRAS spheroids at a concentration of 0.1 µM. 
Furthermore, the area of HKe3-mtKRAS spheroids with 0.1 and 0.5 µM of BrdU was 
larger than that of 3-deaza-cytarabine at day 17 (Figure 4C), suggesting that the 
cytotoxicity of 3-deaza-cytarabine is stronger than that of BrdU. 
 
Discussion 
In this study, it was demonstrated for the first time that BrUrd derivatives selectively 
reduce the growth of CRC spheroids with mtKRAS. In particular, the structure of 3-
deaza-cytarabine is similar to both BrUrd and cytarabine (Table I). The uracil of BrUrd 
and the cytosine of cytarabine are similar in structure and both BrUrd and 3-deaza-
cytarabine have arabinose as the sugar component which is thought to be the part 
that is incorporated into the DNA. Because 3-deaza-cytarabine lacks a nitrogen at the 
position 3 of the cytosine of cytarabine, 3-deaza-cytarabine correctly belongs to 3-
deaza-cytidine analogue. Since, 3-deaza uridine has been demonstrated to have 
significant antitumor activity (20), 3-deaza-cytarabine may also possess strong 
antitumor properties.  
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     BrUrd, EdU and BrdU have been reported to be used for measuring DNA 
incorporation (21, 22). Recent work also suggested that these uridine analogues may 
play a role in the strong suppression of cancer cell proliferation (23-25). Notably, the 
uridine analogue, EdU was more strongly incorporated into newly synthesized DNA 
from Hke3-mtKRAS cells than from HKe3-wtKRAS cells in 2D and 3DF cultures 
(Figure 1). From the view of structural similarities between BrUrd and 3-deaza-
cytarabine (Table I), both analogues may selectively suppress the growth of mtKRAS 
tumours via the acceleration of DNA incorporation.  
3-deaza-cytarabine belongs to a set of cytidine analogues which include cytarabine 
and gemcitabine. Growth suppression by 3-deaza-cytarabine is stronger than 
cytarabine in 2D culture (Figure 3B) and its cytotoxicity is lower than gemcitabine in 
long term 3DF culture (Figure 4C). Because the growth of HKe3-mtKRAS spheroids 
represent in vivo CRC growth and HKe3-wtKRAS spheroids represent the growth of 
normal colonic crypts in vivo (14), the selective suppression of 3-deaza-cytarabine for 
HKe3-mtKRAS spheroids indicates the utility of 3-deaza-cytarabine as an anticancer 
agent with low toxicity for tumours with mtKRAS. Furthermore, the suppressive effect 
of cytarabine is reported to be very weak for solid tumors (26) and the clinical use of 
gemcitabine is often limited due to primary/acquired drug resistance (27). Therefore, 
there is still room to further develop/improve novel nucleoside analogues used for the 
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treatment of cancer patients with mtKRAS.  
Using our culture system and scoring method (Table II), other compounds have 
already been identified in our lab showing selective effects for tumours with mtKRAS 
in 3D microenvironments and having different structures to BrUrd (data not shown). . 
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Figures and Figure legends 
 
Figure 1. 5-ethynyl-2’-deoxyuridine (EdU) incorporation in HKe3-wild type (wt) KRAS 
and HKe3-mutant (mt) KRAS cells grown in 2D and 3DF culture. A: Treatment scheme 
for EdU in 2D and 3DF culture. B, C: Left, middle and right panels: The signals for 
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hoechst33342 (blue), EdU (red) and merged (merge) in HKe3-wtHKe3 (upper panels) 
and HKe3-mtHKe3 cells (lower panels) treated with EdU in 2D (B) and 3DF (C) culture, 
respectively. Scale bar=100 μm.  
 
 
Figure 2. 5-bromouridine (BrUrd) derivatives inhibit growth of HKe3-mutant (mt) KRAS 
spheroids. A: Treatment scheme for BrUrd derivatives in three-dimensional floating 
(3DF) culture. Arrow represents the measurement of area of spheroids. B: Relative 
area of spheroids for HKe3-wild type (wt) KRAS and HKe3-mtKRAS with BrUrd 
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derivatives at day 3 and day 7 against that for HKe3-wtKRAS with dimethyl sulfoxide 
(DMSO) control at day 3. *p<0.05. **p<0.01. C: Relative area of spheroids for HKe3-
wtKRAS and HKe3-mtKRAS with DMSO control and BrUrd derivatives at day 7 
against that at day 3, respectively.  
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Figure 3. The effect of cytidine analogues for HKe3-wild type (wt) KRAS and HKe3-
mutant (mt) KRAS cells grown in 2D culture. A: Treatment scheme for cytarabine, 3-
deaza-cytarabine, and gemcitabine in 2D culture. B, C and D: Relative growth rates of 
HKe3-wtKRAS and HKe3-mtKRAS with cytarabine (B), 3-deaza cytarabine (C) and 
Gemcitabine (D) treatment in 3DF culture at day 6. *p<0.05. n.s.: Not significant. 
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Figure 4.  The long-term effect of 5-Bromo-2'-deoxyuridine (BrdU), 3-deaza 
cytarabine, and Gemcitabine for HKe3- wild type (wt) KRAS and-mutant (mt) KRAS 
spheroids. A: Treatment scheme for 5-Brdu, 3-deaza cytarabine, and gemcitabine in 
3DF culture.  Arrow represents the measurement of the area of spheroids by B:  
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Relative area of spheroids for HKe3-wtKRAS (left panel) and HKe3-mtKRAS (right 
panel) spheroids with 3-deaza cytarabine from day 3 to day 27 against that for HKe3-
wtKRAS with dimethyl sulfoxide (DMSO) control at day 3. C: Pictures of spheroids 
(#1~#3) for HKe3-wtKRAS (upper panel) and HKe3-mtKRAS (lower panel) spheroids 
with DMSO, BrdU (left panel), 3-deaza cytarabine (middle panel), and gemcitabine 
(right panel) at day 17. 
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